HIV DNA vaccine - University of Oxford

Drug Profile

HIV DNA vaccine - University of Oxford

Alternative Names: DNA.MVA vaccine; HIV-1 gag polyepitope/Modified vaccinia virus Ankara vaccine; HIVA.MVA vaccine; Modified vaccinia virus Ankara/HIV-1 gag polyepitope vaccine; MVA vaccine; MVA.HIVA vaccine

Latest Information Update: 28 Aug 2006

Price : $50

At a glance

  • Originator University of Nairobi; University of Oxford
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 28 Aug 2006 Discontinued - Phase-I for HIV infections treatment in United Kingdom (Intradermal)
  • 10 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the adverse events and Viral Infections immunogenicity section
  • 22 Feb 2005 Phase-I clinical trials in HIV infections treatment in United Kingdom (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top